| abstract |
Pharmaceutical compositions and methods for treatment of eye disorders employ ocular hypotensive compounds of the formula (I); ##STR1## (wherein: R 1 is selected from hydrogen, C 1 -C 6 alkyl, and C 1 -C 6 alkoxy; n each R 2 is selected from hydrogen, C 1 -C 6 alkyl, halogen, nitro or carboxy; n R 3 is selected from heterocyclic, amino, mono-substituted amino, and di-substituted amino, n A and B each represents C 1 -C 6 alkylene, n X represents --NH-- or --CH 2 --; and n is 1, 2 or 3) n or pharmaceutically acceptable salts or esters thereof. |